Product Description
IPI-493 is a potent inhibitor of heat shock protein 90 (Hsp90) and is orally bioavailable via a novel formulation. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00724425)
Mechanisms of Action: HSP90 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Chronic Myeloid Leukemia|Oncology Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01193491 |
IPI-493-02 | P1 |
Terminated |
Chronic Myeloid Leukemia |
2011-07-01 |
2019-03-19 |
Treatments |
|
NCT00724425 |
IPI-493-01 | P1 |
Terminated |
Oncology Unspecified |
2011-07-01 |
2019-03-18 |
Treatments |